Soreide Law Group has been receiving calls from our clients who purchased MabVax Therapeutics Holdings, Inc. (MBVX) and experienced significant stock losses. Not only were the brokers from Laidlaw and Company offering this stock, but Laidlaw also served as the “Sole Placement Agent” for the offering. Securities that are newly issued are typically more volatile than the older more established companies, and if the investor was not looking to speculate, this could have been an unsuitable recommendation given to you by your broker from Laidlaw and Company.
According to Yahoo Finance, MabVax Therapeutics Holdings, Inc. (MBVX), is a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.
In June of 2013, MabVax Therapeutics Holdings, Inc. (MBVX) was trading around 261.33, and today it is trading at approximately 1.76. The 52-week change is -67.25%.
On Laidlaw and Company’s website, the following information on their company is given: ”Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets.”
If you’ve experienced significant investment losses in MabVax Therapeutics Holdings, Inc. (MBVX)due to the recommendations of a Laidlaw and Company securities broker, call Soreide Law Group for a no cost consultation with an experienced securities lawyer regarding the possible recovery of your financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents clients nationwide before FINRA. We operate on a contingency fee basis, no fee if no recovery.
The recent Chapter 11 bankruptcy filing by Inspired Healthcare Capital (IHC) has sent shockwaves through the senior living investment community. For many retirees and 1031 exchange participants, what was marketed as a stable, income-producing real estate opportunity has turned into a complex legal battle for recovery. If you invested in an IHC-sponsored Delaware Statutory Trust […]
Soreide Law Group is investigating potential investor claims involving NLCA VA Birmingham Realty DST, particularly where brokers or financial advisors may have improperly recommended this specific Delaware Statutory Trust offering. NLCA VA Birmingham Realty DST is a 1031 exchange investment vehicle that offered investors fractional interests in real estate through a private placement. Although it […]
Investors have reportedly disputed the sales practices of securities broker Nicholas Cross Ignatowski (also known as Nick Ignatowski) [CRD: 2409399, Milwaukee, Wisconsin], based on publicly available information found on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Ignatowski worked for LPL Financial LLC from August 20, 2013, to December 31, 2023. Investors are encouraged to continue reading […]
Phone:
Fax: 1-954-760-6553
Email: info@securitieslawyer.com